Lilly marks the grand opening of its Kenosha site expansion

Eli Lilly and Company marked the opening of an expansion at its Kenosha County, Wisconsin site on August 20, 2026. The facility performs injectable finishing work for the company's incretin medicines, including tirzepatide products Zepbound and Mounjaro ^[1].

Lilly acquired the Kenosha property in 2024 and announced a $3 billion investment plan for the site ^[1]. According to Serafino Fabiano, the site's associate vice president and lead, the company moved from acquisition to FDA approval and active medicine production in about 18 months ^[1]. He said the Kenosha facility has been "actively making medicine" since November of last year, specifically producing Zepbound and Mounjaro ^[1]. Lilly did not release incremental output figures tied to the newly opened expansion ^[1].

The Kenosha site is expected to support 750 "highly skilled jobs," including operators, technicians, engineers and scientists, while the construction phase is projected to support thousands of jobs over several years ^[1]. Fabiano said construction is ongoing, with cranes still active at the site as of the podcast interview ^[1].

Kenosha is one piece of a much larger buildout. Lilly has said it will commit more than $50 billion to US manufacturing since 2020, according to Fabiano ^[1], a figure also cited in a separate report that says Lilly's total domestic investment has surpassed $50 billion, with $23 billion of that committed between 2020 and 2024 ^[2]. That earlier $23 billion included the Kenosha acquisition and expansion alongside new sites in North Carolina, the LEAP Innovation District in Lebanon, Indiana, and expanded facilities in Indianapolis ^[2]. Lilly's broader plans also call for four additional new US manufacturing sites, three focused on active pharmaceutical ingredients and one more parenteral, or injectable, facility, expected to create more than 3,000 high-skilled jobs and nearly 10,000 construction jobs ^[2].

Why it matters for patients

For people currently taking or considering Zepbound or Mounjaro, more finishing capacity at sites like Kenosha is one part of the supply picture drugmakers point to when discussing whether enough medicine can reach pharmacies. Neither source in this report provides current fill rates, wait times, or a specific volume increase tied to the Kenosha expansion itself, so it is not possible to say from this reporting how much closer this specific project brings supply to demand ^[1][2].

What is documented is that Lilly has been steadily adding domestic manufacturing capacity since 2020, and that Kenosha has already been producing tirzepatide products since November of the prior year ^[1]. Patients who experienced shortages of tirzepatide products during the past several years may see continued investment as one signal that the company is working to build more durable supply, though the sources here do not include independent verification of pharmacy-level availability ^[1][2].

What happens next

Construction at the Kenosha site is ongoing, and Fabiano said additional capacity is still being built ^[1]. Lilly's separate plan for four new manufacturing sites, three for active pharmaceutical ingredients and one more injectable facility, has been announced but the sources do not include locations, opening dates, or projected production volumes for those additional sites ^[2]. No figures on Kenosha's specific output following this expansion have been published ^[1].